Participants intending to join the question-and-answer segment must register through the company's designated portal, while a general webcast will be accessible to the public. Management suggests logging in at least 15 minutes before the broadcast begins. A full replay of the discussion will be posted to the firm's investor relations page approximately two hours after the live event concludes.

REGENXBIO continues to focus on its AAV gene therapy platform, which currently supports a portfolio of late-stage trials. Key projects include RGX-202 for Duchenne muscular dystrophy, the AbbVie-partnered ABBV-RGX-314 for retinal conditions, and the Nippon Shinyaku-partnered treatments for MPS I and MPS II. The company’s technology also underpins ZOLGENSMA, a treatment marketed by Novartis.